Literature DB >> 22622579

Sustained translational repression by eIF2α-P mediates prion neurodegeneration.

Julie A Moreno1, Helois Radford, Diego Peretti, Joern R Steinert, Nicholas Verity, Maria Guerra Martin, Mark Halliday, Jason Morgan, David Dinsdale, Catherine A Ortori, David A Barrett, Pavel Tsaytler, Anne Bertolotti, Anne E Willis, Martin Bushell, Giovanna R Mallucci.   

Abstract

The mechanisms leading to neuronal death in neurodegenerative disease are poorly understood. Many of these disorders, including Alzheimer's, Parkinson's and prion diseases, are associated with the accumulation of misfolded disease-specific proteins. The unfolded protein response is a protective cellular mechanism triggered by rising levels of misfolded proteins. One arm of this pathway results in the transient shutdown of protein translation, through phosphorylation of the α-subunit of eukaryotic translation initiation factor, eIF2. Activation of the unfolded protein response and/or increased eIF2α-P levels are seen in patients with Alzheimer's, Parkinson's and prion diseases, but how this links to neurodegeneration is unknown. Here we show that accumulation of prion protein during prion replication causes persistent translational repression of global protein synthesis by eIF2α-P, associated with synaptic failure and neuronal loss in prion-diseased mice. Further, we show that promoting translational recovery in hippocampi of prion-infected mice is neuroprotective. Overexpression of GADD34, a specific eIF2α-P phosphatase, as well as reduction of levels of prion protein by lentivirally mediated RNA interference, reduced eIF2α-P levels. As a result, both approaches restored vital translation rates during prion disease, rescuing synaptic deficits and neuronal loss, thereby significantly increasing survival. In contrast, salubrinal, an inhibitor of eIF2α-P dephosphorylation, increased eIF2α-P levels, exacerbating neurotoxicity and significantly reducing survival in prion-diseased mice. Given the prevalence of protein misfolding and activation of the unfolded protein response in several neurodegenerative diseases, our results suggest that manipulation of common pathways such as translational control, rather than disease-specific approaches, may lead to new therapies preventing synaptic failure and neuronal loss across the spectrum of these disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22622579      PMCID: PMC3378208          DOI: 10.1038/nature11058

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  34 in total

1.  A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress.

Authors:  Michael Boyce; Kevin F Bryant; Céline Jousse; Kai Long; Heather P Harding; Donalyn Scheuner; Randal J Kaufman; Dawei Ma; Donald M Coen; David Ron; Junying Yuan
Journal:  Science       Date:  2005-02-11       Impact factor: 47.728

2.  Activation of the unfolded protein response in Parkinson's disease.

Authors:  J J M Hoozemans; E S van Haastert; P Eikelenboom; R A I de Vos; J M Rozemuller; W Scheper
Journal:  Biochem Biophys Res Commun       Date:  2007-01-17       Impact factor: 3.575

3.  Regulated translation initiation controls stress-induced gene expression in mammalian cells.

Authors:  H P Harding; I Novoa; Y Zhang; H Zeng; R Wek; M Schapira; D Ron
Journal:  Mol Cell       Date:  2000-11       Impact factor: 17.970

4.  The unfolded protein response is activated in Alzheimer's disease.

Authors:  J J M Hoozemans; R Veerhuis; E S Van Haastert; J M Rozemuller; F Baas; P Eikelenboom; W Scheper
Journal:  Acta Neuropathol       Date:  2005-06-23       Impact factor: 17.088

5.  Mice devoid of PrP are resistant to scrapie.

Authors:  H Büeler; A Aguzzi; A Sailer; R A Greiner; P Autenried; M Aguet; C Weissmann
Journal:  Cell       Date:  1993-07-02       Impact factor: 41.582

6.  Cap-independent polysomal association of natural mRNAs encoding c-myc, BiP, and eIF4G conferred by internal ribosome entry sites.

Authors:  G Johannes; P Sarnow
Journal:  RNA       Date:  1998-12       Impact factor: 4.942

7.  A role for motoneuron subtype-selective ER stress in disease manifestations of FALS mice.

Authors:  Smita Saxena; Erik Cabuy; Pico Caroni
Journal:  Nat Neurosci       Date:  2009-03-29       Impact factor: 24.884

8.  Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration.

Authors:  G R Mallucci; S Ratté; E A Asante; J Linehan; I Gowland; J G R Jefferys; J Collinge
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

9.  Disease-associated prion protein oligomers inhibit the 26S proteasome.

Authors:  Mark Kristiansen; Pelagia Deriziotis; Derek E Dimcheff; Graham S Jackson; Huib Ovaa; Heike Naumann; Anthony R Clarke; Fijs W B van Leeuwen; Victoria Menéndez-Benito; Nico P Dantuma; John L Portis; John Collinge; Sarah J Tabrizi
Journal:  Mol Cell       Date:  2007-04-27       Impact factor: 17.970

10.  Flavonol activation defines an unanticipated ligand-binding site in the kinase-RNase domain of IRE1.

Authors:  R Luke Wiseman; Yuhong Zhang; Kenneth P K Lee; Heather P Harding; Cole M Haynes; Joshua Price; Frank Sicheri; David Ron
Journal:  Mol Cell       Date:  2010-04-23       Impact factor: 19.328

View more
  288 in total

Review 1.  Protein misfolding in the endoplasmic reticulum as a conduit to human disease.

Authors:  Miao Wang; Randal J Kaufman
Journal:  Nature       Date:  2016-01-21       Impact factor: 49.962

Review 2.  Retinal Failure in Diabetes: a Feature of Retinal Sensory Neuropathy.

Authors:  Ellyn J Gray; Thomas W Gardner
Journal:  Curr Diab Rep       Date:  2015-12       Impact factor: 4.810

3.  ALS-linked protein disulfide isomerase variants cause motor dysfunction.

Authors:  Ute Woehlbier; Alicia Colombo; Mirva J Saaranen; Viviana Pérez; Jorge Ojeda; Fernando J Bustos; Catherine I Andreu; Mauricio Torres; Vicente Valenzuela; Danilo B Medinas; Pablo Rozas; Rene L Vidal; Rodrigo Lopez-Gonzalez; Johnny Salameh; Sara Fernandez-Collemann; Natalia Muñoz; Soledad Matus; Ricardo Armisen; Alfredo Sagredo; Karina Palma; Thergiory Irrazabal; Sandra Almeida; Paloma Gonzalez-Perez; Mario Campero; Fen-Biao Gao; Pablo Henny; Brigitte van Zundert; Lloyd W Ruddock; Miguel L Concha; Juan P Henriquez; Robert H Brown; Claudio Hetz
Journal:  EMBO J       Date:  2016-02-11       Impact factor: 11.598

Review 4.  Prions and the potential transmissibility of protein misfolding diseases.

Authors:  Allison Kraus; Bradley R Groveman; Byron Caughey
Journal:  Annu Rev Microbiol       Date:  2013-06-28       Impact factor: 15.500

Review 5.  The discovery and consequences of the central role of the nervous system in the control of protein homeostasis.

Authors:  Veena Prahlad
Journal:  J Neurogenet       Date:  2020-06-12       Impact factor: 1.250

Review 6.  Gene Therapy Strategies to Restore ER Proteostasis in Disease.

Authors:  Vicente Valenzuela; Kasey L Jackson; Sergio P Sardi; Claudio Hetz
Journal:  Mol Ther       Date:  2018-04-07       Impact factor: 11.454

7.  eIF2α phosphorylation controls thermal nociception.

Authors:  Arkady Khoutorsky; Robert E Sorge; Masha Prager-Khoutorsky; Sophie Anne Pawlowski; Geraldine Longo; Seyed Mehdi Jafarnejad; Soroush Tahmasebi; Loren J Martin; Mark H Pitcher; Christos G Gkogkas; Reza Sharif-Naeini; Alfredo Ribeiro-da-Silva; Charles W Bourque; Fernando Cervero; Jeffrey S Mogil; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

8.  TRNA mutations that affect decoding fidelity deregulate development and the proteostasis network in zebrafish.

Authors:  Marisa Reverendo; Ana R Soares; Patrícia M Pereira; Laura Carreto; Violeta Ferreira; Evelina Gatti; Philippe Pierre; Gabriela R Moura; Manuel A Santos
Journal:  RNA Biol       Date:  2014       Impact factor: 4.652

Review 9.  Therapies for human prion diseases.

Authors:  Peter K Panegyres; Elizabeth Armari
Journal:  Am J Neurodegener Dis       Date:  2013-09-18

10.  Prion disease tempo determined by host-dependent substrate reduction.

Authors:  Charles E Mays; Chae Kim; Tracy Haldiman; Jacques van der Merwe; Agnes Lau; Jing Yang; Jennifer Grams; Michele A Di Bari; Romolo Nonno; Glenn C Telling; Qingzhong Kong; Jan Langeveld; Debbie McKenzie; David Westaway; Jiri G Safar
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.